Can This Maverick Biotech Become the Frontrunner in the Fight Against Alzheimer’s?

If you had invested $10,000 in shares of mid-cap biotech Cassava Sciences (NASDAQ: SAVA) at the beginning of the year, your position would have grown to a stunning $99,650 as of Feb. 3. With the stock achieving 10-bagger status in a little over a month, many investors wonder if tRead MoreMarketsMarkets Feed